Almonertinib plus carboplatin and pemetrexed
Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions
Non Small Cell Lung Cancer
Phase 3
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation
NCT04500717
Start: 2020-10-31End: 2023-10-31Target: 460Updated: 2020-08-05
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC
NCT04500704
Start: 2020-10-31End: 2023-10-31Target: 166Updated: 2020-08-05